Fungal infection in the intensive care unit

被引:43
作者
Flanagan, PG [1 ]
Barnes, RA [1 ]
机构
[1] Univ Wales Coll Med, Dept Med Microbiol, Cardiff CF4 4XN, S Glam, Wales
关键词
intensive care; Candida spp; colonization versus infection; amphotericin B; fluconazole; exogenous infection;
D O I
10.1016/S0195-6701(98)90271-7
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Fungal infection in critically ill patients is an increasingly prevalent problem. Candida spp. cause the majority of these infections in ICU. They occur most commonly in patients with severe underlying illness, multiple courses of antibiotics and intravascular catheters. Clinical diagnosis is difficult due to nonspecific signs and the frequent occurrence of widespread superficial colonization with Candida spp. in ventilated patients. Most patients are diagnosed using inferential evidence of infection, such as persistent pyrexia despite antibiotics, raised serum C-reactive protein and the presence of individual risk factors. Amphotericin B and fluconazole are the most commonly used anti-fungals dependent on the identity of the fungus. Most of these infections are endogenous; however, a proportion may be caused via the hands of healthcare staff or contaminated medical equipment.
引用
收藏
页码:163 / 177
页数:15
相关论文
共 85 条
[41]   Fungal infections in critically ill patients - Rates are rising but diagnosis and treatment remain difficult [J].
Lipman, J ;
Saadia, R .
BRITISH MEDICAL JOURNAL, 1997, 315 (7103) :266-267
[42]   SEMIQUANTITATIVE CULTURE METHOD FOR IDENTIFYING INTRAVENOUS-CATHETER-RELATED INFECTION [J].
MAKI, DG ;
WEISE, CE ;
SARAFIN, HW .
NEW ENGLAND JOURNAL OF MEDICINE, 1977, 296 (23) :1305-1309
[43]  
Martins M D, 1996, New Horiz, V4, P338
[44]   C-REACTIVE PROTEIN AS A DIAGNOSTIC-TEST OF SEPSIS IN THE CRITICALLY-ILL [J].
MATSON, A ;
SONI, N ;
SHELDON, J .
ANAESTHESIA AND INTENSIVE CARE, 1991, 19 (02) :182-186
[45]   Pneumocystis carinii: Molecular taxonomy and epidemiology [J].
Miller, RF ;
Wakefield, AE .
JOURNAL OF MEDICAL MICROBIOLOGY, 1996, 45 (04) :233-235
[46]   Enolase antigen, mannan antigen, Cand-Tec antigen, and beta-glucan in patients with candidemia [J].
Mitsutake, K ;
Miyazaki, T ;
Tashiro, T ;
Yamamoto, Y ;
Kakeya, H ;
Otsubo, T ;
Kawamura, S ;
Hossain, MA ;
Noda, T ;
Hirakata, Y ;
Kohno, S .
JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (08) :1918-1921
[47]   THERAPEUTIC APPROACHES IN PATIENTS WITH CANDIDEMIA - EVALUATION IN A MULTICENTER, PROSPECTIVE, OBSERVATIONAL STUDY [J].
NGUYEN, MH ;
PEACOCK, JE ;
TANNER, DC ;
MORRIS, AJ ;
NGUYEN, ML ;
SNYDMAN, DR ;
WAGENER, MM ;
YU, VL .
ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (22) :2429-2435
[48]  
NICOLAU DP, 1994, PHARMACOTHERAPY, V73, P145
[49]   Candidemia in non-neutropenic critically ill patients: Analysis of prognostic factors and assessment of systemic antifungal therapy [J].
NollaSalas, J ;
SitgesSerra, A ;
LeonGil, C ;
MartinezGonzalez, JM ;
LeonRegidor, MA ;
IbanezLucia, P ;
TorresRodriguez, JM .
INTENSIVE CARE MEDICINE, 1997, 23 (01) :23-30
[50]   INTRAVENOUS LIPID EMULSIONS AND HOST DEFENSE - A CRITICAL-REVIEW [J].
PALMBLAD, J .
CLINICAL NUTRITION, 1991, 10 (06) :303-308